Videos

Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.

Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.

Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.

Expert discusses the role of venetoclax in the treatment of AML and if achievement of MRD negativity can be used to predict long-term outcomes.

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

Expert discusses the role of FLT3 inhibitors in the treatment of AML and if benefit from midostaurin in combination with chemotherapy can be predicted.

Coadministration of the flu vaccine with other immunizations traditionally offered during flu season that pharmacies should continue to encourage.

Jennifer Adams, PharmD, EdD, leads discussion on reasons for the mild flu season this previous year and share predictions for the upcoming flu season.

Col. Dallas Hack, director of medical affairs at MagicMed, discusses the drug development program of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder.

Cheryl Larson, president and CEO of Midwest Business Group on Health, discusses current efforts to manage drug spend and the high cost of specialty drugs on the market.

Kristin Ferguson, DNP, RN, OCN, outlined 4 principles for the reimbursement of oncology drugs, diagnostics, and biomarker testing that were recently released by the Association of Community Cancer Centers.

In the sixth part of the series, students discussed how their involvement in pandemic-related vaccinations or aid efforts affected how they viewed the field and their role in the field.

Panelists provide tips on how pharmacists can encourage their patients to get their COVID-19 and influenza vaccines this year.

English discussed the challenges and highlights of her time in the trial, in addition to what she feels health care professionals should learn from her own treatment experience.

Dennis Wright, senior director of product marketing for Central Pharmacy Compounding and Dispensing at Omnicell, discusses methods of addressing the rising rate of hospital pharmacist burnout through automation and technology-enabled services.

In the fifth part of the series, students discussed the effects the pandemic had on their future career goals or prospects.

A panel of experts comment on new therapeutic agents being developed and discuss their final thoughts on dry eye disease.

A discussion on the COVID-19 pandemic’s impact on pharmacy staff and solutions to help combat pharmacy staff fatigue, burnout, and vaccine hesitancy.

Douglas Hoey, RPh, MBA, CEO of the National Community Pharmacists Association, addresses how the role of pharmacists, opportunities, and issues facing community pharmacies internationally compare to the experience of community pharmacists in the United States.

Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the FDA’s new guidance Project Optimus, which addresses issues relating to dose optimization in clinical trials assessing oncology drugs.

Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) was approved in July in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma following their first or subsequent relapse.

In the latest Student Cafe interview series, students from the University of Texas at Austin College of Pharmacy discussed the future of pharmacy after the COVID-19 pandemic.

Nicholas Mathews, co-founder of Stillwater Behavioral Health, discusses how pharmacists can respond to the identification of potentially problematic opioid prescription practices at sober-living facilities.

In the latest Student Cafe interview series, students from the University of Texas at Austin College of Pharmacy discussed the future of pharmacy after the COVID-19 pandemic.

Lisa M. Nijm, MD, JD, educates on Eysuvis, an FDA-approved prescription therapeutic for dry eye disease.

John Beckner, RPh, discusses some of the obstacles to achieving herd immunity for COVID-19.

Antonio Ciaccia, CEO of 46brooklyn Research, discusses his company’s efforts to uncover and understand the structure that underlies US drug pricing distortions.

Sharon Park, PharmD, MEd, BCPS, , associate professor and assistant dean for academic affairs at the Notre Dame of Maryland University School of Pharmacy, discusses career options for pharmacy students outside of the traditional roles of a pharmacist.